



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY

**Factors influencing the loco-regional treatment
failure of 3-Dimensional Conformal,
conservative, radiotherapy in laryngeal cancer
patients between January 2015 to December
2018, (Retrospective study)**

A Thesis

Submitted for partial fulfillment of Master Degree
in Clinical Oncology and Nuclear Medicine

By

Amira Ali Emara

MBBCh, Faculty of Medicine, Ain Shams University

Under Supervision of

Prof. Dr. Ehab Mostafa Mohamed

Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University

Prof. Dr. Mahmoud Mahmoud Ellithy

Assistant Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University

Dr. Ahmed Said Ibrahim

Lecturer of Clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University

**Faculty of Medicine
Ain Shams University
2020**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبناك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgments

*First and foremost, I feel always indebted to **Allah**, the **Most Beneficent** and **Merciful**, Who gave me the strength to accomplish this work,*

*My deepest gratitude to my supervisor, **Prof. Dr. Ehab Mostafa Mohamed**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University,, for his valuable guidance and expert supervision, in addition to his great deal of support and encouragement. I really have the honor to complete this work under his supervision.*

*I would like to express my great and deep appreciation and thanks to **Prof. Dr. Mahmoud Mahmoud Ellithy**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for his supervision, and his patience in reviewing and correcting this work,*

*Last but not least, I would like to thank with all appreciation **Dr. Ahmed Said Ibrahim**, Lecturer of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for the efforts and time he has devoted to accomplish this work,*

*Special thanks to my **Parents**, my **sister** and my **brothers**, for their endless support, enduring me and standing by me.*

 *Amira Ali Emara*

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations	i
List of Tables	iv
List of Figures	vi
Introduction	1
Aim of the Work	1
Review of Literature.....	1
Patients and Methods	45
Results.....	53
Discussion	82
Summary	86
Conclusion	89
Recommendations.....	91
References.....	92
Appendices	I
Arabic Summary.....	—

List of Abbreviations

<i>Abbr.</i>	<i>Full-term</i>
AF	: Accelerated fractionation
AHF	: Accelerated hyperfractionation
AJCC	: American Joint Committee on Cancer
AUC	: Area under the curve
CCRT	: Concurrent chemoradiotherapy
CI	: Confidence intervals
CR	: Complete response
CT	: Computed tomography
DFS	: Disease-free survival
ECOG	: Eastern Cooperative Oncology Group
EGFR	: Epidermal growth factor receptor
EORTC	: European Organization for Research and Treatment of Cancer
fr	: Fraction
FU	: Fluorouracil
Gy	: Gray
HF	: Hyperfractionation
HR	: Hazard ratio
IA	: Intra-arterial
IC	: Induction chemotherapy
IMRT	: Intensity modulated radiotherapy
JCOG	: Japan Clinical Oncology Group

KROG	: Korean radiation oncology group
LCR	: Loco-regional control rate
LRC	: Locoregional control
LRFFS	: Locoregional failure free survival
M	: Metastasis stage
MRI	: Magnetic resonance imaging
N	: Nodal stage
NS	: Normal saline
OS	: Overall survival
OTT	: Overall treatment time
pCR	: Pathological complete response
PD	: Progressive Disease
PET	: Positron emission tomography
PF	: Platinol, Fluorouracil
PFS	: Progression-free survival
PR	: Partial response
RCTs	: Randomized controlled trials
RECIST	: Response Evaluation Criteria in Solid Tumors
RT	: Radiotherapy
RTOG	: Radiation Therapy Oncology Group
SCC	: Squamous cell carcinoma
SCL	: Supracricoid partial laryngectomy
SD	: Stable disease
SF	: Standard fractionation
T	: Tumor stage

TL	: Total laryngectomy
TL	: Total laryngectomy
TLM	: Transoral laser microsurgery
TORS	: Transoral robotic surgery
TPF	: Taxotere, Platinol, Fluorouracil
UICC	: Union for International Cancer Control
VA	: Veterans Affairs
GTV	: Gross tumor volume
CTV	: Clinical target volume
PTV	: Planning target volume
TSH	: Thyroid stimulating hormone
3D-CRT	: Three-dimensional conformal radiotherapy

List of Tables

Table No.	Title	Page No.
Table (1):	Patients characteristics (age & sex and performance status).....	54
Table (2):	Patient characteristics (continue).....	55
Table (3):	Tumor characteristics.....	56
Table (4):	Correlation between tumor site and T&N staging.....	57
Table (5):	Treatment received	61
Table (6):	Treatment time and interruptions	62
Table (7):	Pattern of failure	64
Table (8):	LRFFS all patients (Mean and median survival in months)	65
Table (9):	LRFFS & Age.....	66
Table (10):	LRFFS & Sex.....	67
Table (11):	LRFFS & Comorbidity	68
Table (12):	LRFFS & Family history	69
Table (13):	LRFFS & Smoking.....	70
Table (14):	LRFFS & site of tumor	71
Table (15):	LRFFS & T stage.....	72
Table (16):	LRFFS & N stage	73
Table (17):	LRFFS & stage group.....	74
Table (18):	LRFFS & Differentiation.....	75
Table (19):	LRFFS & overall treatment time (weeks)	76

Table (20):	LRFFS & systemic treatment received (Cis/ Carb).....	77
Table (21):	LRFFS & Treatment interruption	78
Table (22):	LRFFS multivariate analysis	79
Table (23):	OS & stage group.....	80